SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 23, 2003
VAXGEN, INC.
(Exact name of Registrant as Specified in its Charter)
DELAWARE 0-26483 94-3236309
(State or other jurisdiction of (Commission (I.R.S. Employer
incorporation or organization) File Number) Identification Number)
1000 MARINA BLVD., SUITE 200 BRISBANE, CALIFORNIA 94005
(Address of Principal Administrative Offices)
Registrants Telephone Number, Including Area Code: (650) 624-1000
Item 5. Other Events.
On June 23, 2003, VaxGen, Inc. announced that it opened its new
biopharmaceutical manufacturing facility in South San Francisco, California.
Item 7. Financial Statements and Exhibits.
(c) Exhibits.
Exhibit No. Description
- ----------- -----------
99.1 Press release issued by VaxGen, Inc. on June 23, 2003.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
VaxGen, Inc.
(Registrant)
Dated: June 24, 2003
By: /s/ Carter A. Lee
---------------------------
Carter Lee
Senior Vice President
Finance & Administration
EXHIBIT INDEX
Exhibit No. Description
- ----------- -----------
99.1 Press release issued by VaxGen, Inc. on June 23, 2003.